Anemia of chronic disease medical therapy

Revision as of 06:59, 2 December 2018 by Shyam Patel (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Anemia of chronic disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anemia of chronic disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anemia of chronic disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anemia of chronic disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anemia of chronic disease medical therapy

CDC on Anemia of chronic disease medical therapy

Anemia of chronic disease medical therapy in the news

Blogs on Anemia of chronic disease medical therapy

Directions to Hospitals Treating Anemia of chronic disease

Risk calculators and risk factors for Anemia of chronic disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

The primary goal in the treatment of anemia of chronic disease is to treat the underlying disease itself. Supplemental iron is recommended, as needed, to keep the transferrin saturation of above 20 percent and a serum ferritin level of above 100 ng/mL. Intravenous iron is more effective than oral supplementaion. Stable patients can be administered synthetically prepared erythropoiesis-stimulating agent such as erythropoietin or darbepoietin. It is important to give oral iron supplementation to all the patients receiving erythropoietin or darbepoetin, in order to maintain a transferrin saturation more than 20 percent and a serum ferritin more than 100 ng/mL. In case of severe disease, blood transfusion is recommended. If the case is underlying malignancy, chemotherapy or radiotherapy may transiently exacerbate anemia due to myelosuppressive effects, but in the long term, it leads to improvement. If the cause is inflammatory disorder, such as rheumatoid arthritis the management of the disease with a disease-modifying antirheumatic drug (DMARD) improves the anemia significantly.

Medical Therapy

The primary goal in the treatment of anemia of chronic disease is to treat the underlying disease itself.[1]

Supplemental iron

  • Supplemental iron is recommended, as needed, to keep the transferrin saturation of above 20 percent and a serum ferritin level of above 100 ng/mL.[3]
  • A variety of oral iron formulations can be used, such as ferrous sulfate.

Intravenous iron

Erythropoietin

In the case of a patient who does not respond to oral iron, parenteral iron infusions erythropoietin should be considered.[4]

Blood Transfusion

  • In case of severe disease, blood transfusion is recommended.
  • Blood transfusions, if performed frequently, can result in iron overload and circulatory overload.

References

  1. Zarychanski R, Houston DS (August 2008). "Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?". CMAJ. 179 (4): 333–7. doi:10.1503/cmaj.071131. PMC 2492976. PMID 18695181.
  2. Cash JM, Sears DA (December 1989). "The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients". Am. J. Med. 87 (6): 638–44. PMID 2589399.
  3. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J (April 2004). "Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial". J. Clin. Oncol. 22 (7): 1301–7. doi:10.1200/JCO.2004.08.119. PMID 15051778.
  4. Spivak JL (August 1994). "Recombinant human erythropoietin and the anemia of cancer". Blood. 84 (4): 997–1004. PMID 8049455.
  5. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, Jenkinson C, Grey-Amante P, Doll H, Wild D (April 2002). "The level of haemoglobin in anaemic cancer patients correlates positively with quality of life". Br. J. Cancer. 86 (8): 1243–9. doi:10.1038/sj.bjc.6600247. PMC 2375336. PMID 11953880.


Template:WikiDoc Sources